Jump to Main Contents
研究所ロゴ

Home > Organization > Divisions and Independent Research Units > Laboratory of Fundamental Oncology > Research Activities

Research Activities

    Original Research Papers

    2023

        1. Yu Chen, Tatsuki Yamamoto, Yura Takahashi, Tomoka Moro, Tomoko Tajima, Yukiko Sakaguchi, Naoaki Sakata, Akihiko Yokoyama, Susumu Hijioka, Akane Sada, Yuko Tabata and Rieko Ohki. Metabolic intervention by low carbohydrate diet suppresses the onset and progression of neuroendocrine tumors. Cell Death & Disease, 14, Article number: 597 (2023) , September 2023.

    2022

        1. Makoto Miyazaki, Ayaka Nakabo, Yoshiko Nagano, Yuko Nagamura, Kazuyoshi Yanagihara, Rieko Ohki, Yoshikazu Nakamura, KiyokoFukami, JunKawamoto, Kenji Umayahara, Masaru Sakamoto, Keiichi Iwaya, and Hideki Yamaguchi. Tissue factor-induced fibrinogenesis mediates cancer cell clustering and multiclonal peritoneal metastasis. Cancer Letters, available online 28 October 2022. https://doi.org/10.1016/j.canlet.2022.215983
        2. Shingo Miyamoto, Yoshiko Nagano, Makoto Miyazaki, Yuko Nagamura, Kazuki Sasaki, Takeshi Kawamura, Kazuyoshi Yanagihara, Toshio Imai, Rieko Ohki, Masakazu Yashiro, Masato Tanaka, Ryuichi Sakai and Hideki Yamaguchi. Integrin α5 mediates cancer cell-fibroblast adhesion and peritoneal dissemination of diffuse-type gastric carcinoma. Cancer Letters, Vol. 526: 335-345, 1 February 2022.

    2021

        1. Megumi Saito, Akane Sada, Masaki Fukuyo, KiyonoAoki, Kazuhiro Okumura, Yuko Tabata, Yu Chen, Atsushi Kaneda, Yuichi Wakabayashi and Rieko Ohki. PHLDA3 is an important downstream mediator of p53 in squamous cell carcinogenesis. Journal of Investigative Dermatology; https://doi.org/10.1016/j.jid.2021.09.007. September 2021.
        2. Ylenia Capodanno, Yu Chen, Joerg Schrader, Mitsuhiro Tomosugi, Shoiciro Sumi, Akihiko Yokoyama, Nobuyoshi Hiraoka and Rieko Ohki. Cross-talk among MEN1, p53 and Notch regulates the proliferation of pancreatic neuroendocrine tumor cells by modulating INSM1 expression and subcellular localization. Neoplasia, Volume 23, Issue 9: 979-992, September 2021.
        3. Yuko Nagamura, Makoto Miyazaki, Yoshiko Nagano, Arata Tomiyama, Rieko Ohki, Kazuyoshi Yanagihara, Ryuichi Sakai, and Hideki Yamaguchi. SHP2 as a Potential Therapeutic Target in Diffuse-Type Gastric Carcinoma Addicted to Receptor Tyrosine Kinase Signaling cancers. Cancers 13(17), 4309; https://doi.org/10.3390/cancers13174309. August 2021.
        4. Aoze Su, Yuko Tabata, Kiyono Aoki, AkaneSada, Rieko Ohki, Satoru Nagatoishi, Kouhei Tsumoto, Siyuan Wang, Yuko Otani, and Tomohiko Ohwada. Elaboration of non-naturally occurring helical tripeptides as p53-MDM2/MDMX interaction inhibitors. Chemical and Pharmaceutical Bulletin, Vol.69, No.7, 681-692; https://doi.org/10.1248/cpb.c21-00238. July 2021.

    2020

        1. Shiori Suzuki, Shuichi Tsutsumi, Yu Chen, Chikako Ozeki, Atsushi Okabe, Tatsuya Kawase, Hiroyuki Aburatani and Rieko Ohki. Identification and characterization of the binding sequences and target genes of p53 lacking the 1st transactivation domain. Cancer Science, 111: 451-466, 2020.

    2019

        1. Shiori Suzuki, Shuichi Tsutsumi, Yu Chen, Chikako Ozeki, Atsushi Okabe, Tatsuya Kawase, Hiroyuki Aburatani and Rieko Ohki. Identification and characterization of the binding sequences and target genes of p53 lacking the 1st transactivation domain. Cancer Science, 13. december 2019.
        2. Shotaro Yamano, Makoto Kimura, Yu Chen, Naoko Imamoto and Rieko Ohki. Nuclear import of IER5 is mediated by a classical bipartite nuclear localization signal and is required for HSF1 full activation. Experimental Cell Research, Article Number: 111686, 2019. (doi: 10.1016/j.yexcr.2019.111686).
        3. AozeSu,Siyuan Wang, Akane Sada,Yuko Otani, Luhan Zhai,Xin Liu,Misa Sayama,Rieko Ohki and Tomohiko Ohwada. Non-naturally occurring helical moleculescan interfere with p53-MDM2 and p53-MDMX protein-protein interactions. Chemical and Pharmaceutical Bulletin, Volume 67 Issue 10: 1139-1143, 2019.
        4. Siyuan Wang, Yuko Otani, Luhan Zhai, Aoze Su, Masayuki Nara, Masatoshi Kawahata, Kentaro Yamaguchi, Akane Sada, Rieko Ohki, Tomohiko Ohwada. Overall Shape Constraint of Alternating /-Hybrid Peptides Containing Bicyclic Proline. Organic Letters, Manuscript No.: ol-2019-02799h (10.1021/acs.orglett.9b02799), 2019
        5. Motohiro Kojima, Yu Chen, Koji Ikeda, Yuichiro Tsukada, Daigoro Takahashi, Shingo Kawano, Kota Amemiya, Masaaki Ito, Rieko Ohki, Atsushi Ochiai. Recommendation of long-term and systemic management according to the risk factors in rectal NETs patients. Scientific Reports 9(1): 2404, 2019.

    2018

        1. Yu Chen, Masahiro Takikawa, Shuichi Tsutsumi, Yoko Yamaguchi, Atsushi Okabe, Mayuna Shibata, Tatsuya Kawase, Akane Sada, Issei Ezawa, Yuhei Takano, Kisaburo Nagata, Yutaka Suzuki, Kentaro Semba, Hiroyuki Aburatani, Rieko Ohki. PHLDA1, another PHLDA family protein that inhibits Akt. Cancer Science, 109: 3532-3542, 2018.
        2. Xiaoqi Wang, Guangyuan Li, Sanjay Koul, Rieko Ohki, Matthew Maurer, Alain Borczuk, Balazs Halmos. PHLDA2 is a key oncogene-induced negative feedback inhibitor of EGFR/ErbB2 signaling via interference with AKT signaling. Oncotarget, 9(38):24914-24926. DOI:10.18632/oncotarget.3674, 2018.
        3. Junko Ohtsuka, Hiroko Oshima, Issei Ezawa, Ryo Abe, Masanobu Oshima and Rieko Ohki. Functional loss of p53 cooperates with the in vivo microenvironment to promote malignant progression of gastric cancers. Scientific Reports 8: 2291, 2018.

    2017

        1. Shigeyuki Magi,Kazunari Iwamoto,Noriko Yumoto,Michio Hiroshima,Takeshi Nagashima,Rieko Ohki, Amaya Garcia-Munoz,Natalia Volinsky,Alexander Von Kriegsheim,Yasushi Sako,Koichi Takahashi, Shuhei Kimura,Boris N. Kholodenko and Mariko Okada-Hatakeyama. Transcriptionally inducible Pleckstrin homology-like domain, family A, member 1, attenuates ErbB receptor activity by inhibiting receptor oligomerization. J Biol Chem, 293: 2206-2218, 2017. (doi:10.1074/jbc.M117.778399)
        2. Naoaki Sakata, Yohko Yamaguchi, Yu Chen, Masayuki Shimoda, Gumpei Yoshimatsu, Michiaki Unno, Shoichiro Sumi, Rieko Ohki. Pleckstrin homology-like domain family A, member 3 (PHLDA3) deficiency improves islets engraftment through the suppression of hypoxic damage. PLoS One, 12(11): e0187927, 2017.
        3. Yuki Yamamoto, Masaki Nagasato, Yosei Rin, Marina Henmi, Yoshinori Ino, Shinichi Yachida, Rieko Ohki, Nobuyoshi Hiraoka, Masatoshi Tagawa and Kazunori Aoki. Strong antitumor efficacy of a pancreatic tumor-targeting oncolytic adenovirus for neuroendocrine tumors. Cancer Medicine, 6(10): 2385-2397, 2017.

    2016

        1. Issei Ezawa, Yuichiro Sawai, Tatsuya Kawase, Atsushi Okabe, Shuichi Tsutsumi, Hitoshi Ichikawa, Yuka Kobayashi, Fumio Tashiro, Hideo Namiki, Tadashi Kondo, Kentaro Semba, Hiroyuki Aburatani, Yoichi Taya, Hitoshi Nakagama and Rieko Ohki. (corresponding author) A novel p53 target gene FUCA1 encodes a fucosidase and regulates growth and survival of cancer cells. Cancer Science, 107(6):734-45, 2016.
        2. Yoshinori Asano, Tatsuya Kawase, Atsushi Okabe, Shuichi Tsutsumi, Hitoshi Ichikawa, Satoko Tatebe, Issay Kitabayashi, Fumio Tashiro, Hideo Namiki, Tadashi Kondo, Kentaro Semba, Hiroyuki Aburatani, Yoichi Taya, Hitoshi Nakagama and Rieko Ohki (corresponding author). IER5 generates a novel hypo-phosphorylated active form of HSF1 and contributes to tumorigenesis. Scientific Reports, 6, 19174, 2016. (doi: 10.1038/srep19174, 2016).

    2015

        1. Xiaoqi Wang, Guangyuan Li, Sanjay Koul, Rieko Ohki, Matthew Maurer, Alain Borczuk, Balazs Halmos. PHLDA2 is a key oncogene-induced negative feedback inhibitor of EGFR/ErbB2 signaling via interference with AKT signaling. Oncotarget, 2015. (doi: 10.18632/oncotarget.3674).
        2. Toshitsugu Fujita, Miyuki Yuno, Daisuke Okuzaki, Rieko Ohki, and Hodaka Fujii. Identification of non-coding RNAs associated with telomeres by enChIP-RNA-Seq. PLoS One, 10, e0123387, 2015.

    2014

        1. Rieko Ohki#, Kozue Saito, Yu Chen, Tatsuya Kawase3, Yukie Aita, Nobuyoshi Hiraoka, Raira Saigawa, Maiko Minegishi, Goichi Yanai, Hiroko Shimizu, Shinichi Yachida, Naoaki Sakata, Akihiko Yokoyama, Ryuichiro Doi, Tomoo Kosuge, Kazuaki Shimada, Benjamin Tycko, Toshihiko Tsukada, Yae Kanai, Shoichiro Sumi, Hideo Namiki, Yoichi Taya, Tatsuhiro Shibata and Hitoshi Nakagama. (#corresponding author) PHLDA3 is a novel tumor suppressor of pancreatic neuroendocrine tumors. Proc Natl Acad Sci USA, 111 (23), E2404-E2413, 2014.　

    2013

        1. Toshitsugu Fujita, Yoshinori Asano, Junko Ohtsuka, Yoko Takada, Kazunobu Saito, Rieko Ohki, Hodaka Fujii. Identification of telomere-associated molecules by engineered DNA-binding molecule-mediated chromatin immunoprecipitation (enChIP). Scientific Reports, 3, doi:10.1038/srep03171, 2013. 　

    2011

        1. Chikako Ozeki, Tatsuhiro Shibata, Takashi Kohno, Yuichiro Sawai, Koji Okamoto, Jun Yokota, Fumio Tashiro, Seiichi Tanuma, Ryuichi Sakai, Tatsuya Kawase, Issay Kitabayashi, Yoichi Taya and Rieko Ohki#. (#corresponding author) Cancer susceptibility polymorphism of p53 at codon 72 affects phosphorylation and degradation of p53 protein. Journal of Biological Chemistry, Vol. 286, pp. 18251-18260, 2011.

    2009

        1. Tatsuya Kawase*, Rieko Ohki#, *, Tatsuhiro Shibata, Shuichi Tsutsumi, Naoko Kamimura, Johji Inazawa, Tsutomu Ohta, Hitoshi Ichikawa, Hiroyuki Aburatani, Fumio Tashiro and Yoichi Taya. (*These authors equally contributed to the work, #corresponding author) PH domain-only protein PHLDA3 is a p53-regulated repressor of Akt. Cell, Vol. 136, pp. 535-550, 2009.

    2008

        1. Tatsuya Kawase, Hitoshi Ichikawa, Tsutomu Ohta, Naohito Nozaki, Fumio Tashiro, Rieko Ohki# and Yoichi Taya#. (#corresponding author) p53 target gene AEN is an exonuclease required for p53-dependent apoptosis. Oncogene, Vol. 27, pp. 3797-810, 2008.

    2007

        1. Rieko Ohki*, Tatsuya Kawase*, Tsutomu Ohta, Hitoshi Ichikawa and Yoichi Taya. (*These authors equally contributed to the work) Dissecting functional roles of p53 N-terminal transactivation domains by microarray expression analysis. Cancer Science, Vol. 98, pp. 189-200, 2007.

    Reviews

    English Reviews

        1. Jayaraman Krishnaraj, Tatsuki Yamamoto and Rieko Ohki. p53-Dependent Cytoprotective Mechanisms behind Resistance to Chemo-Radiotherapeutic Agents Used in Cancer Treatment. Cancers, 15(13), 3399, June 2023.
        2. Yu Chen and Rieko Ohki. p53-PHLDA3-Akt Network: The Key Regulators of Neuroendocrine Tumorigenesis. Int. J. Mol. Sci., 21(11), 4098, 2020.
        3. Tatsuya Kawase, Yu Chen, Rieko Ohki.  IER5 Is a p53-Regulated Activator of HSF1 That Contributes to Promotion of Cancer.  Heat Shock Proteins in Signaling Pathways, Chapter 13, Heat Shock Proteins, Vol. 17, pp. 253-272, 2019.
        4. Masahiro Takikawa and Rieko Ohki (corresponding author). A vicious partnership between AKT and PHLDA3 to facilitate neuroendocrine tumors.
          Cancer Science, 108(6):1101-1108, 2017.
        5. Rieko Ohki and Fuyuki Ishikawa. Telomerase in cancer and senescence.
 Molecular Medicine, vol. 36, pp. 1316-1323, 1999.
        6. Rieko Ohki and Nobuyuki Tanaka. IRF-1 as a regulator of cell cycle, proliferation and oncogenesis. Experimental Medicine, vol. 15, pp. 1956-1961, 1997.
        7. Ryoiti Kiyama, Shinichi Inoue, Rieko Ohki, Eriko Kikuya, Hiroshi Yokota and Michio Oishi. A differential cloning procedure for rearranged or altered genomic DNA based on in-gel competitive reassociation. Advances in Biophysics, vol. 31, pp. 151-161, 1995.

    Japanese Reviews

      1. 大木理恵子. PHLDA3は神経内分泌腫瘍のがん抑制遺伝子であり、悪性化の抑制に寄与する. 胆と膵（2月号）, Vol. 43 No. 2, pp.99-105, 2022.
      2. 大木 理恵子. 膵神経内分泌腫瘍のゲノム異常とプレシジョン・メディシンへの応用. 肝胆膵, 79巻6号（12月号）, pp.1135-1140, 2019.
      3. Kohei Tominaga, Yu Chen and Rieko Ohki. PHLDA3 Determines the Destiny of Pancreatic Neuroendocrine Tumors. Clinical Gastroenterology, Vol. 33, No.9, pp1099-1109, 2018.
      4. Mitsuhiro Tomosugi, Tatsuya Kawase, Kohei Tominaga and Rieko Ohki. Tumor Suppressor Gene PHLDA3, One of the Most Important Molecules to Conquer Pancreatic Neuroendocrine Tumor. Tan to Sui, Vol. 38, pp1345-1355, 2017.
      5. Rieko Ohki. Long known but is still not fully discovered, the most famous tumor suppressor gene p53. Experimental Medicine, Vol. 35, No.14, 2017.
      6. Tatsuya Kawase, Rieko Ohki. Identification and functional analysis of a novel p53 target gene IER5 that has beneficial roles for tumor progression. Experimental Medicine, Vol. 35, No.14, 2017.
      7. 大木 理恵子. 概論—古くても、まだまだ新しい、最も有名ながん抑制遺伝子p53. 実験医学, 35, pp. 2322-2328, 2016.
      8. 川瀬 竜也, 大木 理恵子. p53の新たな細胞保護、がん化促進経路. 実験医学, 35, pp. 2335-2339, 2016.
      9. 滝川 雅大, 大木 理恵子. 野生型・変位型p53を標的とした抗がん剤の現状. 実験医学, 35, pp. 2367-2368, 2016.
      10. IER5は新規の低リン酸化型の活性化HSF1を誘導し、がん化を促進する. 浅野良則, 大木理恵子. 実験医学, 34, pp. 1783-1785, 2016.
      11. 陳 ヨ, 斉藤 梢, 山口 陽子, 大木 理恵子. 膵神経内分泌腫瘍の新規がん抑制遺伝子PHLDA3の発見. 胆と膵, Vol. 36 No.6, 2015 年 6 月: 515-523.
      12. 山口 陽子, 斉藤 梢, 陳 ヨ, 大木 理恵子. 新規がん抑制遺伝子PHLDA3によるAkt経路の制御機構と治療への展開 −膵神経内分泌腫瘍の個別化医療開発を目指して−. 実験医学, 7月 増刊号: 135-143, 2014.
      13. 川瀬 竜也, 大木 理恵子. PHLDA3は新規Akt抑制因子であり、癌化を抑制する因子である. 細胞工学, Special Review, vol. 29, pp. 599-605, 2010.
      14. 大木 理恵子, 川瀬 竜也. PHLDA3は新規Akt抑制因子であり、癌化を抑制する因子である. 生体の科学, vol. 61, pp. 560-567, 2010.
      15. 大木 理恵子, 田矢 洋一.  p53によるアポトーシス制御のメカニズム. バイオ研究マスターシリーズ 細胞死・アポトーシス集中マスター, pp. 71-80, 2006.
      16. Rieko Ohki and Fuyuki Ishikawa. Telomerase in cancer and senescence. Molecular Medicine, vol. 36, pp. 1316-1323, 1999.
      17. Rieko Ohki and Nobuyuki Tanaka. IRF-1 as a regulator of cell cycle, proliferation and oncogenesis. Experimental Medicine, vol. 15, pp. 1956-1961, 1997.
    • Our Research Focus